Symbol | Exchange | Currency |
|---|
ImmunoGen (NASDAQ:IMGN), Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall...
Immunogen (IMGN) reported Q4 EPS of ($0.23), $0.07 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $41.17 million versus the consensus estimate of...
Investing.com - ImmunoGen (NASDAQ: IMGN) reported first quarter EPS of $-0.230, $0.07 better than the analyst estimate of $-0.300. Revenue for the quarter came in at $41.17M versus...
1. Cloudera, Inc. (NYSE:CLDR) broke out of a platform on Wednesday that has been forming for 7 or 8 weeks. It popped 74 cents, or 8 1/2%, to 9.39, just 4 cents off the session...
1. Allied Healthcare Products (AHPI) AHPI which I have been following for two months, exploded at the end of February, worked its way back down, and on Monday, it reversed, going...
Benchmarks ended were mixed on Friday, as investors’ attention was fixed on the rising death toll in China and the limited strength displayed by American consumers last...
ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.
| Average | 12.000 (+215.375% Upside) |
| High | 22.000 |
| Low | 3.000 |
| Price | 3.805 |
| No. of Analysts | 12 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Strong Buy | Neutral | Sell | Strong Sell |
| Technical Indicators | Strong Buy | Strong Buy | Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Neutral | Strong Sell | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 190.94 | 195.28 | 189.44 | +1.75 | +0.93% | 55.47M | NASDAQ | |||
| 159.79 | 160.30 | 159.35 | +2.14 | +1.36% | 17.11M | NASDAQ | |||
| 61.90 | 61.95 | 61.59 | +0.48 | +0.78% | 2.38M | NYSE | |||
| 203.09 | 203.99 | 202.54 | +2.41 | +1.20% | 5.68M | NASDAQ | |||
| 101.24 | 112.02 | 100.65 | +0.21 | +0.21% | 10.55M | NASDAQ | |||
| 279.10 | 280.65 | 278.41 | +3.87 | +1.41% | 7.92M | NASDAQ | |||
| 40.22 | 40.25 | 39.99 | +0.23 | +0.58% | 3.95M | NYSE | |||
| 95.61 | 96.91 | 94.87 | +1.05 | +1.11% | 23.13M | NASDAQ | |||
| 99.46 | 100.29 | 98.58 | +2.22 | +2.28% | 19.34M | NASDAQ | |||
| 161.52 | 161.53 | 160.15 | +2.54 | +1.60% | 432.77K | NASDAQ | |||
| 268.16 | 270.67 | 265.97 | +4.06 | +1.54% | 16.48M | NASDAQ | |||
| 8.12 | 8.25 | 8.05 | +0.12 | +1.56% | 6.03M | NYSE | |||
| 101.64 | 102.79 | 101.04 | +0.28 | +0.27% | 9.32M | NASDAQ | |||
| 45.83 | 46.44 | 44.75 | +1.52 | +3.43% | 6.25M | NYSE | |||
| 10.27 | 10.27 | 10.24 | 0.00 | 0.00% | 0.00 | NYSE |